"1-2" . "RIV/00064173:_____/12:43907010!RIV13-MZ0-00064173" . . "Terapie akutn\u00EDho koron\u00E1rn\u00EDho syndromu (AKS)proch\u00E1z\u00ED v sou\u010Dasn\u00E9 dob\u011B mohutn\u00FDm rozvojem d\u00EDky v\u00FDvoji nov\u00FDch antitrombotik. Dostupn\u00E9 znalosti o nov\u00FDch peror\u00E1ln\u00EDch protidesti\u010Dkov\u00FDch l\u00E9c\u00EDch lze shrnout n\u00E1sledovn\u011B: 1) Nov\u00E9 l\u00E9ky (prasugrel a ticagrelor) sou rychlej\u0161\u00ED, \u00FA\u010Dinn\u011Bj\u0161\u00ED a maj\u00ED p\u0159edv\u00EDdateln\u011Bj\u0161\u00ED \u00FA\u010Dinek ne\u017E clopidogrel, proto tak\u00E9 clopidogrel m\u016F\u017Ee b\u00FDt t\u011Bmito l\u00E9ky nahrazen u v\u011Bt\u0161iny pacient\u016F s AKS; 2) zd\u00E1 se, \u017Ee prasugrel m\u00E1 v\u00FDrazn\u011Bj\u0161\u00ED okam\u017Eit\u00FD \u00FA\u010Dinek zejm\u00E9na u pacient\u016F s infarktem myokardu s elevacemi \u00FAseku ST (STEMI), z tohoto d\u016Fvudu by m\u011Bl b\u00FDt u STEMI up\u0159ednost\u0148ov\u00E1n, a to zejm\u00E9na v akutn\u00ED f\u00E1zi; 3) ticagrelor m\u00E1 lep\u0161\u00ED \u00FA\u010Dinky v oblasti dlouhodob\u00E9 sekund\u00E1rn\u00ED prevence, z \u010Deho\u017E mohou t\u011B\u017Eit pacienti s akutn\u00EDm non-STEMI; a \u010D) oba nov\u00E9 l\u00E9ky maj\u00ED sv\u00E9 kontraindikace, ne\u017E\u00E1douc\u00ED \u00FA\u010Dinky a jsou v\u00FDrazn\u011B dra\u017E\u0161\u00ED, v d\u016Fsledku \u010Deho\u017E bude m\u00EDt clopidegrol st\u00E1le sv\u00E9 m\u00EDsto v l\u00E9\u010Db\u011B vybran\u00FDch skupin paient\u016F."@cs . . "I" . . "Rozvoj nov\u00FDch l\u00E9\u010Debn\u00FDch postup\u016F u akutn\u00EDho koron\u00E1rn\u00EDho syndromu pomoc\u00ED peror\u00E1ln\u00ED protidesti\u010Dkov\u00E9 l\u00E9\u010Dby"@cs . "Evolving strategies in the management of acute coronary syndromes with oral antiplatelet agents"@en . . . "Evolving strategies in the management of acute coronary syndromes with oral antiplatelet agents"@en . . . . . "Ticagrelor; Prasugrel; Oral antiplatelet drugs; Clopidogrel; Acute myocardial infarction; Acute coronary syndrome"@en . "Rozvoj nov\u00FDch l\u00E9\u010Debn\u00FDch postup\u016F u akutn\u00EDho koron\u00E1rn\u00EDho syndromu pomoc\u00ED peror\u00E1ln\u00ED protidesti\u010Dkov\u00E9 l\u00E9\u010Dby"@cs . . "1"^^ . "54" . "Cor et Vasa" . "The treatment of acute coronary syndromes (ACS) is currently undergoing an interesting evolution due to the introduction of some novel antithrombotic drugs. The available evidence on new oral antiplatelet agents can be summarized as follows: (1) the new drugs (prasugrel and ticagrelor) are faster, more potent, and more predictable than clopidogrel, and thus prasugrel or ticagrelor may replace clopidogrel in most patients with ACS; (2) prasugrel seems to have a more pronounced acute effect, especially in patients with acute ST-elevation myocardial infarction (STEMI), and thus prasugrel may be the preferred drug for STEMI, especially for the acute phase; (3) ticagrelor seems to have better secondary preventive effects in the long term, which may be advantageous for patients with acute non-STEMI; and (4) both new drugs have some contraindications or unpleasant side effects and are both substantially more expensive, which may keep a place in therapy for clopidogrel for selected patients"@en . "0010-8650" . . "166452" . . "[8BA25C9E56CF]" . "Terapie akutn\u00EDho koron\u00E1rn\u00EDho syndromu (AKS)proch\u00E1z\u00ED v sou\u010Dasn\u00E9 dob\u011B mohutn\u00FDm rozvojem d\u00EDky v\u00FDvoji nov\u00FDch antitrombotik. Dostupn\u00E9 znalosti o nov\u00FDch peror\u00E1ln\u00EDch protidesti\u010Dkov\u00FDch l\u00E9c\u00EDch lze shrnout n\u00E1sledovn\u011B: 1) Nov\u00E9 l\u00E9ky (prasugrel a ticagrelor) sou rychlej\u0161\u00ED, \u00FA\u010Dinn\u011Bj\u0161\u00ED a maj\u00ED p\u0159edv\u00EDdateln\u011Bj\u0161\u00ED \u00FA\u010Dinek ne\u017E clopidogrel, proto tak\u00E9 clopidogrel m\u016F\u017Ee b\u00FDt t\u011Bmito l\u00E9ky nahrazen u v\u011Bt\u0161iny pacient\u016F s AKS; 2) zd\u00E1 se, \u017Ee prasugrel m\u00E1 v\u00FDrazn\u011Bj\u0161\u00ED okam\u017Eit\u00FD \u00FA\u010Dinek zejm\u00E9na u pacient\u016F s infarktem myokardu s elevacemi \u00FAseku ST (STEMI), z tohoto d\u016Fvudu by m\u011Bl b\u00FDt u STEMI up\u0159ednost\u0148ov\u00E1n, a to zejm\u00E9na v akutn\u00ED f\u00E1zi; 3) ticagrelor m\u00E1 lep\u0161\u00ED \u00FA\u010Dinky v oblasti dlouhodob\u00E9 sekund\u00E1rn\u00ED prevence, z \u010Deho\u017E mohou t\u011B\u017Eit pacienti s akutn\u00EDm non-STEMI; a \u010D) oba nov\u00E9 l\u00E9ky maj\u00ED sv\u00E9 kontraindikace, ne\u017E\u00E1douc\u00ED \u00FA\u010Dinky a jsou v\u00FDrazn\u011B dra\u017E\u0161\u00ED, v d\u016Fsledku \u010Deho\u017E bude m\u00EDt clopidegrol st\u00E1le sv\u00E9 m\u00EDsto v l\u00E9\u010Db\u011B vybran\u00FDch skupin paient\u016F." . . "7"^^ . . "7"^^ . . "Rozvoj nov\u00FDch l\u00E9\u010Debn\u00FDch postup\u016F u akutn\u00EDho koron\u00E1rn\u00EDho syndromu pomoc\u00ED peror\u00E1ln\u00ED protidesti\u010Dkov\u00E9 l\u00E9\u010Dby" . "CZ - \u010Cesk\u00E1 republika" . . "RIV/00064173:_____/12:43907010" . . . "Rozvoj nov\u00FDch l\u00E9\u010Debn\u00FDch postup\u016F u akutn\u00EDho koron\u00E1rn\u00EDho syndromu pomoc\u00ED peror\u00E1ln\u00ED protidesti\u010Dkov\u00E9 l\u00E9\u010Dby" . "Widimsk\u00FD, Petr" .